3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
124
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Recurrence
18
Burkitt Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms, Plasma Cell
7
Neoplasms
7
Immunoglobulin Light-chain Amyloidosis
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma
6
Leukemia, Biphenotypic, Acute
6
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
4
Lung Neoplasms
4
Leukemia
4
Waldenstrom Macroglobulinemia
3
Nausea
3
Colorectal Neoplasms
3
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
toripalimab
4
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
Radiation
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
camrelizumab
2
Taxes
2
Nivolumab
2
Injections
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Dexamethasone
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled